4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          YUKAWA is a 12-week, randomized, double-blind, placebo-controlled, phase 2 study evaluating the efficacy and safety of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk.

          Related collections

          Author and article information

          Journal
          Circ. J.
          Circulation journal : official journal of the Japanese Circulation Society
          1347-4820
          1346-9843
          2014
          : 78
          : 5
          Affiliations
          [1 ] Division of Cardiology, Department of Medicine, Nihon University School of Medicine.
          Article
          DN/JST.JSTAGE/circj/CJ-14-0130
          24662398
          ef4660fa-fc68-41f5-8a3b-e06b423e7282
          History

          Comments

          Comment on this article